Clinical trials: Mesothelioma
Mesothelioma
A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma
Based on results from earlier clinical trials, Pemetrexed may have antitumor activity as a first-line agent in the treatment of mesothelioma.
- Trial name
- NCT00190762
- Testing
- Pemetrexed
- Where
- Canada
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
Mesothelioma
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
This research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma. The drugs involved in this study are: Durvalumab Tremelimumab
- Trial name
- NCT03075527
- Testing
- Tremelimumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
ER+ Breast Cancer, Ovarian Cancer
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
This Phase 1b is a dose escalation, MTD expansion and cohort expansions study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.
- Conditions
- ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT03983954
- Testing
- Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab
- Where
- 9 sites in India, Israel
- Volunteers
- 120 people
- Sponsor
- NeoTX Therapeutics Ltd.
Malignant Pleural Mesothelioma
Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
The purpose of this study is to evaluate the safety of combining chemotherapy at different doses with a specific type of radiation therapy delivered to the entire lining of the lung to find out what effects, if any, it has on…
- Trial name
- NCT02639767
- Testing
- Pemetrexed/Cisplatin, Pleural Intensity Modulated Radiation Therapy, MRI
- Where
- 6 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Pleural Mesothelioma
Four Versus Six Cycles of Pemetrexed/Platinum for MPM
The prognosis of mesothelioma is generally poor. The median survival of patients with unresectable malignant mesothelioma ranges approximately between 6-12 months. Survival is poor because there is no curative treatment.
- Trial name
- NCT02497053
- Testing
- pemetrexed/platinum chemotherapy
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Mesothelioma, Pleural Mesothelioma
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.
- Conditions
- Mesothelioma, Pleural Mesothelioma, Wilms Tumor
- Trial name
- NCT04040231
- Testing
- Galinpepimut-S, Nivolumab, Sargramostim
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Glioblastoma
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors.
- Conditions
- Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma
- Trial name
- NCT05538572
- Testing
- PRT3645
- Where
- 13 sites in United States, Singapore
- Volunteers
- 22 people
- Sponsor
- Prelude Therapeutics Incorporated
Malignant Pleural Mesothelioma
Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment
Combination of gemcitabine-cisplatin was one of the most effective chemotherapy treatment in mesothelioma patients. However, median survival of this patient group was only about 12 months.
- Trial name
- NCT01243632
- Testing
- Prolonged 6-hr infusion of gemcitabine
- Where
- Slovenia
- Volunteers
- 78 people
- Sponsor
- Institute of Oncology Ljubljana
Pleural Malignant Mesothelioma
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
This phase I trial studies the side effects and best way to give pembrolizumab after radiation therapy in treating patients with pleural malignant mesothelioma.
- Trial name
- NCT02959463
- Testing
- Laboratory Biomarker Analysis, Palliative Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
This trial is to determine the safest dose of a triple combination (chemokine modulatory regimen or CKM) of celecoxib, interferon alfa (IFN), and rintatolimod that can be given with a DC vaccine as treatment of peritoneal surface…
- Conditions
- Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
- Trial name
- NCT02151448
- Testing
- DC vaccine, Celecoxib, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- David Bartlett
Solid Tumors
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03926143
- Testing
- BAY94-9343 (Anetumab ravtansine)
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 9 people
- Sponsor
- Bayer
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Ovarian Cancer, Peritoneal Cancer
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
To determine treatment response to surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies: Gynecologic cancers (ovarian, primary peritoneal or fallopian…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Uterine Cancer
- Trial name
- HIPEC/IPHC (NCT02349958)
- Testing
- HIPEC: MMC 30mg @ T0, 10mg @ T45min, HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0, HIPEC: CDDP 75 mg/m2 @T0
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bay Area Gynecology Oncology
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural…
- Conditions
- Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
- Trial name
- NCT01064648
- Testing
- Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis
- Where
- 230 sites in United States
- Volunteers
- 117 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma, Diagnoses Disease
Real World Study of MPM in China
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with atypical clinical manifestations. Most patients with MPM are at an advanced stage at the time of diagnosis, and only a few patients can be cured by radical…
- Conditions
- Malignant Pleural Mesothelioma, Diagnoses Disease, Treatments, Prognosis
- Trial name
- NCT05042557
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Chinese Academy of Medical Sciences
Pleural Mesothelioma, Malignant Pleural Mesothelioma
Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate
The purposes of this study are: to evaluate the effects (good and bad) that administering heated cisplatin into the chest and abdomen cavity following surgical resection has on malignant mesothelioma; to collect data on the…
- Trial name
- NCT00165516
- Testing
- Cisplatin, Sodium Thiosulfate
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Dana-Farber Cancer Institute
Mesothelioma
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma.
- Trial name
- ATOMIC (NCT02709512)
- Testing
- ADI-PEG 20 plus Pem Platinum
- Where
- 45 sites in United States, Australia and 3 more
- Volunteers
- 249 people
- Sponsor
- Polaris Group
Malignant Mesothelioma
IP3R Modulation by Cancer Genes in Mesothelioma
Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction
- Trial name
- NCT03558932
- Testing
- pleural biopsy
- Volunteers
- 20 people
- Sponsor
- KU Leuven
Mesothelioma
Combination Gene Transfer and Chemotherapy
The purpose of this study is to find the safety of combination gene therapy and chemotherapy in patients with malignant pleural mesothelioma.
- Trial name
- NCT01119664
- Testing
- SCH 721015
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)